{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T03:52:36Z","timestamp":1781927556325,"version":"3.54.5"},"reference-count":32,"publisher":"Japanese Society of Internal Medicine","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,6,15]]},"DOI":"10.2169\/internalmedicine.6058-25","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T22:07:08Z","timestamp":1762985228000},"page":"1586-1593","source":"Crossref","is-referenced-by-count":0,"title":["Effect of Sodium-Glucose Cotransporter-2 Inhibitors on Frailty in Patients with Heart Failure"],"prefix":"10.2169","volume":"65","author":[{"given":"Shun","family":"Kitamura","sequence":"first","affiliation":[{"name":"Division of Cardiology, Mitsui Memorial Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Horiuchi","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Mitsui Memorial Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Nishimura","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Mitsui Memorial Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Nemoto","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Mitsui Memorial Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Gonda","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Mitsui Memorial Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Yoshiura","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Mitsui Memorial Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Asami","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Mitsui Memorial Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Taniwaki","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Mitsui Memorial Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitomi","family":"Yuzawa","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Mitsui Memorial Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kota","family":"Komiyama","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Mitsui Memorial Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Mitsui Memorial Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Tanabe","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Mitsui Memorial Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Vitale C, Jankowska E, Hill L, et al. Heart Failure Association\/European Society of Cardiology position paper on frailty in patients with heart failure. Eur J Heart Fail 21: 1299-1305, 2019.","DOI":"10.1002\/ejhf.1611"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Matsue Y, Kamiya K, Saito H, et al. Prevalence and prognostic impact of the coexistence of multiple frailty domains in elderly patients with heart failure: the FRAGILE-HF cohort study. Eur J Heart Fail 22: 2112-2119, 2020.","DOI":"10.1002\/ejhf.1926"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Kinugasa Y, Yamamoto K. The challenge of frailty and sarcopenia in heart failure with preserved ejection fraction. Heart 103: 184-189, 2017.","DOI":"10.1136\/heartjnl-2016-309995"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Thanapholsart J, Khan E, Ismail TF, Lee GA. The complex pathophysiology of cardiac cachexia: a review of current pathophysiology and implications for clinical practice. Am J Med Sci 365: 9-18, 2023.","DOI":"10.1016\/j.amjms.2022.08.016"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Butt JH, Dewan P, Jhund PS, et al. Sacubitril\/valsartan and frailty in patients with heart failure and preserved ejection fraction. J Am Coll Cardiol 80: 1130-1143, 2022.","DOI":"10.1016\/j.jacc.2022.06.037"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Khan H, Kalogeropoulos AP, Georgiopoulou VV, et al. Frailty and risk for heart failure in older adults: the health, aging, and body composition study. Am Heart J 166: 887-894, 2013.","DOI":"10.1016\/j.ahj.2013.07.032"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Denfeld QE, Winters-Stone K, Mudd JO, Gelow JM, Kurdi S, Lee CS. The prevalence of frailty in heart failure: a systematic review and meta-analysis. Int J Cardiol 236: 283-289, 2017.","DOI":"10.1016\/j.ijcard.2017.01.153"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Kitai T, Kohsaka S, Kato T, et al.; Japanese Circulation Society and the Japanese Heart Failure Society Joint Working Group. JCS\/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure. Circ J 89: 1278-1444, 2025.","DOI":"10.1253\/circj.CJ-25-0002"},{"key":"9","unstructured":"9. McMurray JJV, Solomon SD, Inzucchi SE, et al.; DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381: 1995-2008, 2019."},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. Packer M, Anker SD, Butler J, et al. Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction: the EMPEROR-reduced trial. Circulation 143: 326-336, 2021.","DOI":"10.1161\/CIRCULATIONAHA.120.051783"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Nassif ME, Windsor SL, Borlaug BA, et al. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med 27: 1954-1960, 2021.","DOI":"10.1038\/s41591-021-01536-x"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Zelniker TA, Braunwald E. Cardiac and renal effects of sodium-glucose co-transporter 2 inhibitors in diabetes: JACC state-of-the-art review. J Am Coll Cardiol 72: 1845-1855, 2018.","DOI":"10.1016\/j.jacc.2018.06.040"},{"key":"13","doi-asserted-by":"publisher","unstructured":"13. Gilbert T, Neuburger J, Kraindler J, et al. Development and validation of a Hospital Frailty Risk Score focusing on older people in acute care settings using electronic hospital records: an observational study. Lancet 391: 1775-1782, 2018.","DOI":"10.1016\/S0140-6736(18)30668-8"},{"key":"14","doi-asserted-by":"crossref","first-page":"ooad035","DOI":"10.1093\/jamiaopen\/ooad035","volume":"6","author":"MB Palchuk","year":"2023","unstructured":"14. Palchuk MB, London JW, Perez-Rey D, et al. A global federated real-world data and analytics platform for research. JAMIA Open 6: ooad035, 2023.","journal-title":"JAMIA Open","ISSN":"https:\/\/id.crossref.org\/issn\/2574-2531","issn-type":"print"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Horiuchi Y, Wettersten N, Asami M, et al. Glucagon-like peptide-1 receptor agonists improve outcomes in individuals with type 2 diabetes with and without heart failure. Int J Cardiol 418: 132611, 2025.","DOI":"10.1016\/j.ijcard.2024.132611"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Abu-Qaoud MR, Kumar A, Tarun T, et al. Impact of SGLT2 inhibitors on AF recurrence after catheter ablation in patients with type 2 diabetes. JACC Clin Electrophysiol 9: 2109-2118, 2023.","DOI":"10.1016\/j.jacep.2023.06.008"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Green JB, Bethel MA, Armstrong PW, et al.; TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373: 232-242, 2015.","DOI":"10.1056\/NEJMx150029"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Filippatos G, Anker SD, Butler J, et al.; EMPEROR-Reduced Trial Committees and Investigators. Effects of empagliflozin on cardiovascular and renal outcomes in heart failure with reduced ejection fraction according to age: a secondary analysis of EMPEROR-reduced. Eur J Heart Fail 24: 2297-2304, 2022.","DOI":"10.1002\/ejhf.2707"},{"key":"19","unstructured":"19. B\u00f6hm M, Butler J, Filippatos G, Ferreira JP, et al.; EMPEROR-Preserved Trial Committees and Investigators. Empagliflozin improves outcomes in patients with heart failure and preserved ejection fraction irrespective of age. J Am Coll Cardiol 80: 1-18, 2022."},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Bhatt AS, Kosiborod MN, Vaduganathan M, et al. Effect of dapagliflozin on health status and quality of life across the spectrum of ejection fraction: Participant-level pooled analysis from the DAPA-HF and DELIVER trials. Eur J Heart Fail 25: 981-988, 2023.","DOI":"10.1002\/ejhf.2909"},{"key":"21","unstructured":"21. Abraham WT, Lindenfeld J, Ponikowski P, et al. Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes. Eur Heart J 42: 700-710, 2021."},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Naser JA, Tada A, Harada T, et al. Effects of dapagliflozin on body composition and its relation to hemodynamics in heart failure with preserved ejection fraction. Circulation 149: 2026-2028, 2024.","DOI":"10.1161\/CIRCULATIONAHA.124.069479"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Nambu H, Takada S, Fukushima A, et al. Empagliflozin restores lowered exercise endurance capacity via the activation of skeletal muscle fatty acid oxidation in a murine model of heart failure. Eur J Pharmacol 866: 172810, 2020.","DOI":"10.1016\/j.ejphar.2019.172810"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Jaul E, Barron J, Rosenzweig JP, Menczel J. An overview of co-morbidities and the development of pressure ulcers among older adults. BMC Geriatr 18: 305, 2018.","DOI":"10.1186\/s12877-018-0997-7"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Pollock C, Stef\u00e1nsson B, Reyner D, et al. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 7: 429-441, 2019.","DOI":"10.1016\/S2213-8587(19)30086-5"},{"key":"26","doi-asserted-by":"publisher","unstructured":"26. Hiriscau EI, Bodolea C. The role of depression and anxiety in frail patients with heart failure. Diseases 7: 45, 2019.","DOI":"10.3390\/diseases7020045"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Wium-Andersen IK, Osler M, J\u00f8rgensen MB, Rungby J, Wium-Andersen MK. Antidiabetic medication and risk of dementia in patients with type 2 diabetes: a nested case-control study. Eur J Endocrinol 181: 499-507, 2019.","DOI":"10.1530\/EJE-19-0259"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Katsuumi G, Shimizu I, Suda M, et al. SGLT2 inhibition eliminates senescent cells and alleviates pathological aging. Nat Aging 4: 926-938, 2024.","DOI":"10.1038\/s43587-024-00642-y"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Martinez FA, Serenelli M, Nicolau JC, et al. Efficacy and safety of dapagliflozin in heart failure with reduced ejection fraction according to age: insights from DAPA-HF. Circulation 141: 100-111, 2020.","DOI":"10.1161\/CIRCULATIONAHA.119.044133"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Hacil A, Antakly Hanon Y, Lacour A, et al. Efficacy and safety of SGLT2 inhibitors in heart failure: observational evidence in geriatric patients AGING-HF. Circ Heart Fail 20: e012794, 2025.","DOI":"10.1161\/CIRCHEARTFAILURE.125.012794"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Horiuchi Y, Asami M, Yahagi K, et al. Sodium-glucose cotransporter-2 inhibitors in heart failure with malnutrition, frailty, sarcopenia, or cachexia. J Clin Med 13: 1670, 2024.","DOI":"10.3390\/jcm13061670"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Adamson C, Jhund PS, Docherty KF, et al. Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index. Eur J Heart Fail 23: 1662-1672, 2021.","DOI":"10.1002\/ejhf.2308"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/12\/65_6058-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T03:37:23Z","timestamp":1781926643000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/12\/65_6058-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.6058-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]},"article-number":"6058-25"}}